ALN-TTRSC (Revusiran)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for ALN-TTRSC (Revusiran), covering 2023-03-20 to 2023-03-20. Get the full timeline:
Most recent: Clinical Trial Update: Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis [Phase 2]